# Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

> **NCT02057692** · PHASE2 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Alagille Syndrome

## Interventions

- **DRUG:** LUM001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02057692
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-24
- **Primary completion:** 2016-11-16
- **Final completion:** 2016-11-16
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057692, "Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02057692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*